|9.75||+0.2800||+2.96%||Vol 323.63K||1Y Perf 29.02%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||-0.23 -2.36%|
|Target Price||16.43||Analyst Rating||Strong Buy 1.20|
|Potential %||68.51||Finscreener Ranking||+ 38.22|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||+ 35.16|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||+ 28.70|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||65.06||Earnings Rating||Sell|
|Market Cap||557.22M||Earnings Date||7th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.25|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||352.60K|
|Avg. Monthly Volume||664.60K|
|Avg. Quarterly Volume||480.45K|
Evolus Inc. (NASDAQ: EOLS) stock closed at 9.47 per share at the end of the most recent trading day (a -0.53% change compared to the prior day closing price) with a volume of 535.60K shares and market capitalization of 557.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 125 people. Evolus Inc. CEO is David Moatazedi.
The one-year performance of Evolus Inc. stock is 29.02%, while year-to-date (YTD) performance is 26.1%. EOLS stock has a five-year performance of -36.7%. Its 52-week range is between 6.51 and 11.49, which gives EOLS stock a 52-week price range ratio of 65.06%
Evolus Inc. currently has a PE ratio of -5.50, a price-to-book (PB) ratio of 15.03, a price-to-sale (PS) ratio of 4.26, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -38.94%, a ROC of -67.15% and a ROE of -125.45%. The company’s profit margin is -58.35%, its EBITDA margin is -49.00%, and its revenue ttm is $104.97 Million , which makes it $1.87 revenue per share.
Of the last four earnings reports from Evolus Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. Evolus Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Evolus Inc. is Strong Buy (1.2), with a target price of $16.43, which is +68.51% compared to the current price. The earnings rating for Evolus Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evolus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evolus Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 47.16, ATR14 : 0.42, CCI20 : 72.28, Chaikin Money Flow : -0.04, MACD : 0.35, Money Flow Index : 41.90, ROC : 18.38, RSI : 61.45, STOCH (14,3) : 76.55, STOCH RSI : 0.00, UO : 43.78, Williams %R : -23.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evolus Inc. in the last 12-months were: Alphaeon 1 Llc (Sold 1 850 000 shares of value $15 540 000 ), Avelar Rui (Sold 14 906 shares of value $126 254 ), Beaver Sandra (Sold 3 178 shares of value $30 827 ), David Moatazedi (Sold 70 321 shares of value $595 548 ), Inc. Medytox (Sold 2 224 554 shares of value $19 002 799 ), Moatazedi David (Sold 70 321 shares of value $595 619 ), Rui Avelar (Sold 14 906 shares of value $126 237 ), Vikram Malik (Buy at a value of $1 296 505)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.